New
Vitiligo Study For Children Ages 2–11 in USA and Canada
Clinical trial · Children ages 2–11 · United States and Canada
The TRuE-ViP study is evaluating ruxolitinib cream for children with nonsegmental vitiligo. Here is the short version—what the study asks, what families should consider, and where to learn more.
See if your child may qualify →Study at a glance
Ages: 2–11 years
Condition: Nonsegmental vitiligo
Locations: Selected sites in the United States and Canada
Time: Up to 14 months, including 11 study visits
Study: TRuE-ViP / TRuE-VIP1 · NCT06548360
Why this study?
Ruxolitinib cream—sold as Opzelura—is approved in the United States and Canada for nonsegmental vitiligo in people ages 12 and older. This study asks whether it is safe and effective for younger children.
Children are not simply smaller adults. Researchers need evidence from children themselves before anyone can answer that question. The results are not yet known—that is the point of the trial.
Who may qualify?
- Children ages 2 to 11
- A diagnosis of nonsegmental vitiligo
- Vitiligo affecting no more than 10% of the body
The study also needs measurable vitiligo on the face and body. Segmental vitiligo and some other causes of pigment loss are not included. The study team—not your bathroom mirror and a calculator—will make the final eligibility assessment.
Ready to check the basics?
Answer a few initial questions and choose your country. A participating study site will confirm whether screening makes sense.
Check eligibility →What would participation involve?
Up to 30 days to review eligibility and health.
For 24 weeks, children receive ruxolitinib cream or a similar-looking cream without the active medicine. Neither families nor the study team know which one during this period.
Eligible children who continue receive ruxolitinib cream for another 28 weeks.
A safety check about 30 days after the final application.
The cream is applied twice daily. Visits may include skin measurements, photographs, physical checks, blood tests, and questions about symptoms or side effects.
Before you apply: current treatment matters
Participants generally must stop other vitiligo treatments from screening through the final safety follow-up. That may include prescription creams, oral medicines, or phototherapy.
Do not stop treatment on your own. Ask the research team what would need to pause, then discuss it with your child’s regular dermatologist. If the current routine is helping, this may be the biggest part of the decision.
What are researchers measuring?
The main Week 24 result looks at facial vitiligo. Researchers will measure how many children achieve at least a 75% improvement using a standard score called F-VASI.
The 75% figure is a research target, not a promise. Some children may improve more, some less, and some may not improve. Safety and changes elsewhere on the body will also be monitored.
Good questions to ask
- Which treatments would my child need to stop?
- What risks and side effects are known?
- How long are visits, and can they fit around school?
- How often are blood tests, and what support is available?
- Which travel expenses or costs are reimbursed?
- What happens if we decide to leave the study?
It remains your choice
Participation is voluntary. Saying no will not affect your child’s regular care, and families may leave the study later. Depending on age and local rules, the child may also be asked for assent—an explanation they can understand and an invitation to agree.
Consent is not a trapdoor that locks behind you. It is an ongoing choice.
Could this study fit your family?
Visit the official TRuE-ViP website for the full study details, current locations, and a short eligibility check.
Visit the TRuE-ViP study website →Recruitment status and site availability can change. The research team will confirm eligibility and explain the study before enrollment.
Keep exploring
Clinical Trials: An Important Step in Drug Development
How treatments move from the laboratory into human studies—and what each phase is meant to learn.
Vitiligo Patient Journey Map
Diagnosis, treatment, setbacks and daily life, mapped like a subway system.
Not Just Another Cream: Incyte’s Vitiligo Support Story
The science behind ruxolitinib cream and the patient support built around it.
Podcast
Inside Vitiligo Clinical Trials: Why, What and How? (Ep. 25)
A practical conversation about how trials work and what participation can mean.
FAQOther Questions
- Which therapy has minimal side-effects?
Dead Sea climatotherapy is a unique and highly effective treatment option for vitiligo, offering a top-tier safety profile and natural therapeutic benefits. Its combination of p...
- How can I explain vitiligo to my children?
Vitiligo can be confusing for children because it doesn’t resemble an "illness" in the typical sense. Choosing the right way to explain it depends on your child’s age and maturi...
- Белые пятна на теле? Витилиго?
Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что происходи...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.